The multiplicity of potential biomarkers that have been established (PD‐L1 expression, TMB, and dMMR status), as well as the effective integration of pembrolizumab in the first‐line treatment of BRAF mutant melanoma patients, should prompt further investigations in EGFR mutant treatment‐naïve NSCLC patients. This evidence concerns the gene BRAF and melanoma.